Gut metagenomes of NSCLC patients on ICB therapy, Seoul
Cross-sectional study of 51 fecal metagenome samples from NSCLC patients (32 elderly, 19 adult) in Seoul, South Korea, who received anti-PD-L1 immune checkpoint blockade treatment. machine-written summary
51 samples · 51 runs · KR · Adult · 2024 · 17.72 Gbp / sample · cohort A conserved pilin from uncultured gut bacterial cl
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 714 sample values (age, collection date, country, health condition, health condition detail, intervention, intervention detail, latitude) |
| ○ Abstract / description | read; no usable statement |
| ○ Full text | read; no usable statement or table · PMC11680825 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Non-antibiotic pharmaceutical given as the study intervention (metformin design observational_with_procedure · population other_cancer · Anti-PD-L1/anti-PD-1 immune checkpoint blockade therapy
“NSCLC patients who received anti-PD-L1 treatment” — bioproject.description (study level; per-sample arms are in the intervention column below)
Genera, mean relative abundance over 47 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 51 | 100% | ||||
| country | 51 | 100% | 51 | |||
| health_condition | 51 | 100% | 51 | |||
| subject_id | 0 | 0% | ||||
| age_at_collection_days | 51 | 100% | 51 | |||
| collection_date | 51 | 100% | 51 | |||
| detailed_location | 51 | 100% | ||||
| health_condition_detail | 51 | 100% | 51 | |||
| intervention | 51 | 100% | 51 | |||
| intervention_detail | 51 | 100% | 51 | |||
| latitude | 51 | 100% | 51 | |||
| location_locality | 51 | 100% | 51 | |||
| location_region | 51 | 100% | 51 | |||
| longitude | 51 | 100% | 51 | |||
| medication | 51 | 100% | 51 | |||
| medication_detail | 51 | 100% | 51 | |||
| sex | 51 | 100% | 51 |
- A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy. 2024 PMID 39730328 PMC11680825 unsure
Archive description
To identify gut microbiome features associated with immune checkpoint blockade response, we performed whole metagenomic shotgun sequencing on fecal samples of NSCLC patients who received anti-PD-L1 treatment.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult and elderly by sonnet_x2 with confidence 0.72. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- host run.scientific_name · “human gut metagenome”
- body site study.description · “fecal samples of NSCLC patients”
- life stage study.title · “NSCLC patients who received ICB treatment”
- life stage sample.attr.host_age · “72 (n=32/51)”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN42215829 | age_at_collection_days | 26641.0 | R1 | 0.85 | sample.attr.host_age | 73 |
| SAMN42215829 | collection_date | 2021 | R1 | 0.90 | biosample.attribute:collection_date | 2021 |
| SAMN42215829 | country | KR | R1 | 0.90 | sample.attr.geo_loc_name | South Korea: Seoul |
| SAMN42215829 | health_condition | other_cancer | R1 | 0.85 | biosample_attr | NSCLC |
| SAMN42215829 | health_condition_detail | NSCLC | R1 | 0.90 | sample.attr.host_disease | NSCLC |
| SAMN42215829 | intervention | drug_therapy | R1 | 0.90 | biosample.attribute:treatment | treatment: anti-PD-L1 |
| SAMN42215829 | intervention_detail | anti-PD-L1 immune checkpoint blockade therapy | R1 | 0.90 | biosample.attribute:treatment | treatment: anti-PD-L1 |
| SAMN42215829 | latitude | 37.5610 | R1 | 0.90 | biosample.attribute:lat_lon | 37.561 N 126.939 E |
| SAMN42215829 | location_locality | Seoul | R1 | 0.85 | biosample.attribute:geo_loc_name | South Korea: Seoul |
| SAMN42215829 | location_region | Seoul | R1 | 0.60 | biosample.attribute:lat_lon | 37.561 N 126.939 E |
| SAMN42215829 | longitude | 126.9390 | R1 | 0.90 | biosample.attribute:lat_lon | 37.561 N 126.939 E |
| SAMN42215829 | medication | immunosuppressant_or_biologic | R1 | 0.90 | biosample.attribute:treatment | anti-PD-L1 |
| SAMN42215829 | medication_detail | anti-PD-L1 | R1 | 0.90 | biosample.attribute:treatment | anti-PD-L1 |
| SAMN42215829 | sex | male | R1 | 0.90 | sample.attr.host_sex | male |
Sequencing
51 runs over 51 samples · mean 18.02 Gbp per run (median 17.72 Gbp, total 919.21 Gbp; 51 runs with a base count) · layout PAIRED 51 · platform ILLUMINA 51 · models Illumina NovaSeq 6000 (51) · 92% of runs with a Sandpiper profile · first public 2024-12-29
Authors (23)
Kim CY first · Park DJ · Ahn BC · Baek S · Hong MH · Nguyen LT · Hwang SH · Kim N · Podlesny D · Orakov A · Schudoma C · Robbani SM · Shim HS · Yoon HI · Lee CY · Park SY · Yong D · Han M · Bork P · Kim BC · Ha SJ · Kim HR · Lee I last
Downloads
PRJNA1130699.csv.gz (2.5 KB) · parquet (73.2 KB) — all 51 samples, every field with route and confidence · PRJNA1130699_determinations.csv.gz (5.2 KB) — 714 evidence rows